Lannett (LCI) Catches Bid Following Phentermine HCl ANDA Approval
Tweet
Share
E-mailGet Alerts LCI Hot Sheet
Join SI Premium – FREE
Lannett (NYSE: LCI) shares have popped higher following reports the U.S. FDA has approved its Abbreviated New Drug Application (ANDA) of Phentermine HCl Capsules, 37.5 mg.
The stock is up nearly 3 percent on the session this afternoon, after being relatively flat all day.
The stock is up nearly 3 percent on the session this afternoon, after being relatively flat all day.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lyell shifts LYL273 trial timeline, eyes 2027 FDA meeting
- Biohaven stock tumbles after pausing trial enrollment
- Third Arc Bio picks lead candidate in amended Adagene collaboration
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
